NVLX just announced huge breaking news: Nuvilex Announces Name Change to PharmaCyte Biotech (Read Press Release Below) This Could be an Added Catalyst for a Major Breakout! If you haven`t taken a look at NVLX yet, this may be the last chance in this range! Start your research immediately! PRESS RELEASE:
Nuvilex Announces Name Change to PharmaCyte Biotech Company`s Shares Will Trade Under New Ticker Symbol PHCB SILVER SPRING, Md., Jan. 7, 2015 (GLOBE NEWSWIRE) — Nuvilex, Inc.
(NVLX) today announced that the Company has changed its name to PharmaCyte Biotech, Inc. Shares in PharmaCyte Biotech will trade under the new ticker symbol “PHCB” on the OTCQB electronic platform. The new symbol is expected to become effective at the open of the market on January 8, 2014. The name change is part of the Company`s transformation process to operate solely as a pure biotechnology firm leveraging its Cell-in-a-Box(R) technology, a proprietary cell encapsulation platform being utilized to develop “targeted” treatments for solid cancerous tumors and insulin dependent diabetes.
“Over the past year, we`ve implemented an aggressive strategy to facilitate the advancement of the treatments we are developing for cancer and diabetes, with our Cell-in-a-Box(R) technology at the core of these treatments. Our new name reflects the tremendous progress we`ve accomplished in terms of clinical development and signifies the structural completion of our transition to becoming a fully dedicated biotechnology company,” said Kenneth L. Waggoner, Chief Executive Officer of PharmaCyte Biotech.
Some of the highlights in 2014 that have marked this transition include:
Receiving “orphan drug” designation from the U.S. Food and Drug Administration (FDA) for the Company`s pancreatic cancer treatment, with applications filed with the EMA and the TGA for the same status in Europe and Australia.
Development of a clinical protocol for a planned Phase 2b clinical trial with the goal of initiating the clinical trial in 2015.
A preclinical study being completed evaluating the effectiveness of the Company`s pancreatic cancer treatment on the accumulation of malignant ascites fluid often associated with the growth of abdominal cancers with positive results that have led to a follow-up study about to be launched.
The establishment of a world-wide Diabetes Consortium with a number of research agreements now in place with major universities and institutions that will permit the development of a break-through treatment for insulin dependent diabetes that combines Cell-in-a-Box(R) with insulin-producing cells.
Progression at the University of Northern Colorado in the pursuit of treatments for brain and other forms of difficult to treat cancers that will combine cannabinoid or cannabinoid-like compounds with the Cell-in-a-Box(R) technology.
“With exciting developments on the horizon for 2015, our work to develop treatments for both cancer and diabetes will move forward under our new name because it speaks to what we actually do here at PharmaCyte Biotech,” concluded Mr. Waggoner.
About PharmaCyte Biotech PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box(R). This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built.
PharmaCyte Biotech`s treatment for pancreatic cancer involves low doses of the well-known anticancer prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or “cancer-killing” form. These capsules are placed as close to the cancerous tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. This “targeted chemotherapy” has proven remarkably effective in past clinical trials. In addition, PharmaCyte Biotech is working towards improving the quality of life for patients with advanced pancreatic cancer and on treatments for other types of solid cancerous tumors. PharmaCyte Biotech is also developing treatments for cancer based upon chemical constituents of marijuana known as cannabinoids. In doing so, PharmaCyte Biotech is examining ways to exploit the benefits of Cell-in-a-Box(R) technology in optimizing the anticancer effectiveness of cannabinoids, while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments. This provides PharmaCyte Biotech the rare opportunity to develop “green” approaches to fighting deadly diseases, such as cancer of the pancreas, brain and breast, which affect hundreds of thousands of individuals worldwide every year.
NVLX has taken some HUGE steps forward recently, placing the Company in an excellent position for growth. They have released quite a few significant press releases including today`s breaking news all of which indicate the Company`s Huge Growth potential and there continued ability to hit their Millstones.
NVLX looks to be setting up for a Major Breakout! The strong momentum pushing NVLX means that the bullish upside could lead to a major breakout any minute! I believe we have found what could be the hottest play we have had in recent months… And you all know we are coming off of some huge winners.
If you haven`t taken a look at NVLX yet, this may be the last chance in this range! Start your research immediately at:
www.nuvilex.com Sincerely, Ari Goldstein Editor In Chief, EquityTradingAlert PS. My Incredible Winning Streak Set to Continue! We are Coming off of winners that gained 100% while others witnessed 300%+ within the first hour of trading.
PPS. To make sure you take full advantage of our Newsletter make sure you add our email address: email@example.com to your email program`s safe sender list to ensure that you receive our Newsletter! This will ensure our emails don`t end up in the spam box.
DON`T MISS ANOTHER HOT OPPORTUNITY TO MAKE HUGE PROFITS! GENERAL NOTICE AND DISCLAIMER – PLEASE READ CAREFULLY Please be advised that we have been compensated seven thousand five hundred dollars cash by ACN LLC, a non-affiliated third party to profile NVLX for a two day investor awareness program. WE OWN NO SHARES.
Equity Trading Alert 4417 13th St. Saint Cloud, FL 34769 To